Opening Symposium of the KG Jebsen Centre for Myeloid Blood Cancer, C-MYC

Treatment of aggressive cancers often fails. Patients who do not respond to treatment are not identified until several weeks or months after the treatment initiation, based on measurement of tumor burden. The new center C-MYC will work to change this and use myeloid blood cancer as a model for a paradigm shift in diagnostics and treatment. Tumor diagnostics will develop functional profiling of single cells, so that non-response can be identified within hours or days, rather than weeks or months. Most anticancer drugs direct the fate of tumor cells towards cell death, differentiation, transdifferentiation, quiescence and senescence. With today's diagnostics, this information about cell fate cannot be extracted. The C-MYC center will use measurement of cell fates to identify non-responders and optimize treatment. C-MYC will bring basic researchers together with clinical projects to develop new diagnostic and therapy concepts for future clinical studies in a 5-year period supported by the KG Jebsen Foundation.

C-MYC is hosted by the University of Bergen, in collaboration with Haukeland University Hospital and the University of Oslo. C-MYC opens September 11-12 in Bergen, with scientific opening symposium as well as a patient-oriented meeting together with the Blood Cancer Association on September 12.

Opening Symposium

Registration:  on this link

Venue: Grand Bergen, Nedre Ole Bulls plass 1, 5012 Bergen

Program:

Wednesday 11. September, Grand Bergen
10:30-11:00    Registration, Coffee
11:00-12:00    Opening
11:00-11:10    Bjørn Tore Gjertsen, C-MYC Centre Director
11:15-11:20    Anne Marie Haga, KG Jebsen Foundation
11:25-11:35    Olav Ljøsne, Chair, Blodkreftforeningen
11:35-11:40    Per Bakke, Dean, Medical Faculty, UiB
11:45-11:50    Clara Gjesdal, vice CEO, Haukeland University Hospital
11:55-12:00    Silke Appel, Chair, Department of Clinical Sciences, UiB
12:00-12:05    Kahtan Al-Azawy, Director, Department of Medicine, Haukeland University Hospital

12:05-13:20    Lunch

Scientific Program
13:20-14:00    Molecular Measureable Residual Disease Monitoring in Acute Myeloid Leukemia (AML), Konstanze Döhner
14:00-14:40    Targeting Epigenetics: A new strategy in myeloid cancer prevention? Kirsten Grönbæk
14:40-15:20     What is meant by "responsible" cancer research? Roger Strand, CCBIO, Centre for the Study of the Sciences and the Humanities 
15:20-15:30    Concluding remarks and introduction of Symposium Day 2, Bjørn Tore Gjertsen

(Dinner, Hotel Norge, 19:00, Aperitif 18:30)

Thursday 12. September, Grand Bergen
08:30-09:00    Registration, Coffee
        Chair: BT Gjertsen
09:00-09:20    Demultiplexing cell identity, Simona Chera, KGJ C-MYC
09:20-09:40    Towards single-cell profiling of translation and isoforms, Eivind Valen, KGJ C-MYC
09:40-10:00    Minimal Residual disease in myelodysplastic syndrome, Astrid Olsnes
10:00-10:20    Allogeneic hematopoietic stem cell transplantation for myeloid malignancies - from patient’s bed to multiomics? Håkon Reikvam
10:20-10:30 Pause
        Chair: S Chera
10:30-10:50    AML modelling: Past, present and future directions, Emmet Mc Cormack 
10:50-11:10    How can we make use of the p53 code in the clinic? JC Bourdon
11:10-11:30    Functional precision medicine for overcoming drug resistance in elderly/unfit AML patients, Krister Wennerberg 
11:30-12:00    Clinical forecasting of Acute Myeloid Leukemia by ex vivo drug sensitivity screening, Jorrit Enserink 
12:00-12:50    Lunch
        Chair: E Valen 
12:50-13:10    Generating evidence from Real World Data in hematology, Kimmo Porkka
13:10-13:30    Evolutionary landscape of clonal hematopoiesis, Gerwin Huls
13:30-14:10    Novel candidate targets for future AML therapies: Glycosaminoglycans and DNA-PK, Kim Theilgaard-Mönch
14:10-14:30    Targeting NAMPT in -7/-7q Myeloid Blood Cancers, Caroline Heckman
14:30-14:40    Pause
        Chair: H Reikvam
14:40-15:00    Ex Vivo Venetoclax Sensitivity Testing Predicts Treatment Response in AML, Mika Kontro 
15:00-15:20    A phase 1 study to study 5-FU-mir-15a (CR-001) in AML, Andrea Lenartova
15:20-15:40    Nordic CML Study Group, a Nordic forum for basic and clinical research? Henrik Hjorth-Hansen
15:40-16:00    Quality of life studies in AML in Sweden, Vladimir Lazarevic 
16:00-16:20     Metabolic rewiring as targetable entity in AML, JJ Schuringa
16:20-16:40     Closing remarks, Simona Chera (Co-Director, C-MYC)